vs
Apellis Pharmaceuticals, Inc.（APLS）与null（GPRO）财务数据对比。点击上方公司名可切换其他公司
null的季度营收约是Apellis Pharmaceuticals, Inc.的1.0倍（$201.7M vs $199.9M），null同比增速更快（0.4% vs -5.9%），null自由现金流更多（$15.0M vs $-14.3M），过去两年null的营收复合增速更高（13.9% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
GoPro, Inc.是2002年由尼克·伍德曼创立的美国科技企业，最初注册名为伍德曼实验室，总部坐落于加利福尼亚州圣马特奥。该公司主营运动相机生产制造，同时还自主开发配套移动端应用与视频编辑软件。
APLS vs GPRO — 直观对比
营收规模更大
GPRO
是对方的1.0倍
$199.9M
营收增速更快
GPRO
高出6.3%
-5.9%
自由现金流更多
GPRO
多$29.2M
$-14.3M
两年增速更快
GPRO
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $201.7M |
| 净利润 | $-59.0M | — |
| 毛利率 | — | 31.8% |
| 营业利润率 | -25.6% | -4.1% |
| 净利率 | -29.5% | — |
| 营收同比 | -5.9% | 0.4% |
| 净利润同比 | -62.2% | — |
| 每股收益（稀释后） | $-0.40 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSGPRO
| Q4 25 | $199.9M | $201.7M | ||
| Q3 25 | $458.6M | $162.9M | ||
| Q2 25 | $178.5M | $152.6M | ||
| Q1 25 | $166.8M | $134.3M | ||
| Q4 24 | $212.5M | $200.9M | ||
| Q3 24 | $196.8M | $258.9M | ||
| Q2 24 | $199.7M | $186.2M | ||
| Q1 24 | $172.3M | $155.5M |
净利润APLSGPRO
| Q4 25 | $-59.0M | — | ||
| Q3 25 | $215.7M | $-21.3M | ||
| Q2 25 | $-42.2M | $-16.4M | ||
| Q1 25 | $-92.2M | $-46.7M | ||
| Q4 24 | $-36.4M | — | ||
| Q3 24 | $-57.4M | $-8.2M | ||
| Q2 24 | $-37.7M | $-47.8M | ||
| Q1 24 | $-66.4M | $-339.1M |
毛利率APLSGPRO
| Q4 25 | — | 31.8% | ||
| Q3 25 | — | 35.1% | ||
| Q2 25 | — | 35.8% | ||
| Q1 25 | — | 32.1% | ||
| Q4 24 | — | 34.7% | ||
| Q3 24 | — | 35.5% | ||
| Q2 24 | — | 30.5% | ||
| Q1 24 | — | 34.1% |
营业利润率APLSGPRO
| Q4 25 | -25.6% | -4.1% | ||
| Q3 25 | 48.7% | -9.8% | ||
| Q2 25 | -18.6% | -9.2% | ||
| Q1 25 | -50.0% | -33.7% | ||
| Q4 24 | -12.3% | -19.5% | ||
| Q3 24 | -24.0% | -3.1% | ||
| Q2 24 | -14.7% | -25.0% | ||
| Q1 24 | -36.0% | -26.6% |
净利率APLSGPRO
| Q4 25 | -29.5% | — | ||
| Q3 25 | 47.0% | -13.0% | ||
| Q2 25 | -23.6% | -10.8% | ||
| Q1 25 | -55.3% | -34.8% | ||
| Q4 24 | -17.1% | — | ||
| Q3 24 | -29.2% | -3.2% | ||
| Q2 24 | -18.9% | -25.7% | ||
| Q1 24 | -38.5% | -218.1% |
每股收益（稀释后）APLSGPRO
| Q4 25 | $-0.40 | $-0.06 | ||
| Q3 25 | $1.67 | $-0.13 | ||
| Q2 25 | $-0.33 | $-0.10 | ||
| Q1 25 | $-0.74 | $-0.30 | ||
| Q4 24 | $-0.30 | $-0.22 | ||
| Q3 24 | $-0.46 | $-0.05 | ||
| Q2 24 | $-0.30 | $-0.31 | ||
| Q1 24 | $-0.54 | $-2.24 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $49.7M |
| 总债务越低越好 | — | $44.3M |
| 股东权益账面价值 | $370.1M | $76.5M |
| 总资产 | $1.1B | $428.0M |
| 负债/权益比越低杠杆越低 | — | 0.58× |
8季度趋势，按日历期对齐
现金及短期投资APLSGPRO
| Q4 25 | $466.2M | $49.7M | ||
| Q3 25 | $479.2M | $152.8M | ||
| Q2 25 | $370.0M | $58.6M | ||
| Q1 25 | $358.4M | $69.6M | ||
| Q4 24 | $411.3M | $102.8M | ||
| Q3 24 | $396.9M | $130.2M | ||
| Q2 24 | $360.1M | $133.0M | ||
| Q1 24 | $325.9M | $133.7M |
总债务APLSGPRO
| Q4 25 | — | $44.3M | ||
| Q3 25 | — | $43.9M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | $93.1M | ||
| Q2 24 | — | $92.9M | ||
| Q1 24 | $93.1M | $92.7M |
股东权益APLSGPRO
| Q4 25 | $370.1M | $76.5M | ||
| Q3 25 | $401.2M | $80.5M | ||
| Q2 25 | $156.3M | $97.9M | ||
| Q1 25 | $164.2M | $110.0M | ||
| Q4 24 | $228.5M | $151.7M | ||
| Q3 24 | $237.1M | $183.9M | ||
| Q2 24 | $264.3M | $184.7M | ||
| Q1 24 | $266.7M | $224.9M |
总资产APLSGPRO
| Q4 25 | $1.1B | $428.0M | ||
| Q3 25 | $1.1B | $538.6M | ||
| Q2 25 | $821.4M | $439.0M | ||
| Q1 25 | $807.3M | $462.5M | ||
| Q4 24 | $885.1M | $543.7M | ||
| Q3 24 | $901.9M | $661.6M | ||
| Q2 24 | $904.5M | $556.8M | ||
| Q1 24 | $831.9M | $575.8M |
负债/权益比APLSGPRO
| Q4 25 | — | 0.58× | ||
| Q3 25 | — | 0.55× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | 0.51× | ||
| Q2 24 | — | 0.50× | ||
| Q1 24 | 0.35× | 0.41× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $15.6M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $15.0M |
| 自由现金流率自由现金流/营收 | -7.1% | 7.4% |
| 资本支出强度资本支出/营收 | 0.1% | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $-24.0M |
8季度趋势，按日历期对齐
经营现金流APLSGPRO
| Q4 25 | $-14.2M | $15.6M | ||
| Q3 25 | $108.5M | $12.2M | ||
| Q2 25 | $4.4M | $8.8M | ||
| Q1 25 | $-53.4M | $-57.2M | ||
| Q4 24 | $19.4M | $-25.1M | ||
| Q3 24 | $34.1M | $-2.2M | ||
| Q2 24 | $-8.3M | $605.0K | ||
| Q1 24 | $-133.0M | $-98.4M |
自由现金流APLSGPRO
| Q4 25 | $-14.3M | $15.0M | ||
| Q3 25 | $108.3M | $11.2M | ||
| Q2 25 | $4.4M | $8.3M | ||
| Q1 25 | $-53.4M | $-58.5M | ||
| Q4 24 | $19.3M | $-25.5M | ||
| Q3 24 | — | $-4.2M | ||
| Q2 24 | $-8.4M | $-111.0K | ||
| Q1 24 | $-133.3M | $-99.4M |
自由现金流率APLSGPRO
| Q4 25 | -7.1% | 7.4% | ||
| Q3 25 | 23.6% | 6.9% | ||
| Q2 25 | 2.5% | 5.4% | ||
| Q1 25 | -32.0% | -43.5% | ||
| Q4 24 | 9.1% | -12.7% | ||
| Q3 24 | — | -1.6% | ||
| Q2 24 | -4.2% | -0.1% | ||
| Q1 24 | -77.3% | -63.9% |
资本支出强度APLSGPRO
| Q4 25 | 0.1% | 0.3% | ||
| Q3 25 | 0.0% | 0.6% | ||
| Q2 25 | 0.0% | 0.3% | ||
| Q1 25 | 0.0% | 1.0% | ||
| Q4 24 | 0.0% | 0.2% | ||
| Q3 24 | 0.0% | 0.8% | ||
| Q2 24 | 0.0% | 0.4% | ||
| Q1 24 | 0.2% | 0.6% |
现金转化率APLSGPRO
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
GPRO
| Subscription And Services | $106.3M | 53% |
| Other | $95.4M | 47% |
